Medicxi — Full Portfolio
32 tracked investments · listed companies and verified rows first
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system disorders.
BiotechHealthtechWaltham, US
Joseph Reilly(Executive Officer)Geoff Race(Executive Officer)Fred Ahlholm(Executive Officer)Remy Luthringer(Executive Officer, Director)Mark Levine(Executive Officer)
BoardMichele Ollier(Director)in
Board seatFrancesco De Rubertis· per SEC Form D · $31M raise · filed Mar 2015
Co-investorsVivo Capital
BiotechSouth San Francisco, US
Grant E Pickering(Executive Officer, Director, Promoter)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Board seatMoncef Slaoui· per SEC Form D · $110M raise · filed Apr 2020
Co-investorsAbingworthFrazier Life SciencesPivotal Life SciencesRed Tree Venture
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesDroia VenturesForesite CapitalJazzya InvestmentsMyelin VC+4 more
Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease.
BiotechHealthtechCambridge, US
Niranjan Kameswaran(Chief Executive Officer)Jessica Stromme(Chief Development Officer)Kelly Foster(Chief Scientific Officer)Stephen Huang(Senior Vice President, Head of Clinical Development)Simon Read(Chairman of the Board and Independent Board Member)
Co-investorsAtlas VentureAvoro Capital Advisors
BiotechCollege Park, US
John Clerici(Executive Officer)Andrew Drechsler(Executive Officer)Brett Giroir(Executive Officer, Director)
BoardNicholas Williams(Director)Jon Edwards(Director)
Board seatMoncef Slaoui· per SEC Form D · $75M raise · filed Feb 2026
Co-investorsGRA VenturePitango
BiotechPhiladelphia, US
William Hinshaw(Executive Officer, Director)Jeff Sacher(Chief Financial Officer)Matthew Ros(Chief Executive Officer, President and Secretary)
BoardErez Chimovits(Director)inMatthew Foy(Director)
Board seatGiovanni Mariggi· per SEC Form D · $46M raise · filed May 2025
Co-investors3B Future Health FundOrbiMed
BiotechHenrico, US
Timothy E Ladin(Executive Officer)Andrew N Fleischman(Executive Officer, Director)
BoardManeka Mirchandaney(Director)Ted Love(Director)
Board seatGiovanni Mariggi· per SEC Form D · $69M raise · filed May 2026
Rivus develops oral medicines for cardiometabolic health using its proprietary development platform.
BiotechDigital HealthCharlottesville, US
Allen Cunningham(Executive Officer, Director)Nancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)Shaharyar Khan(Executive Officer, Director)
BoardDerek DiRocco(Director)in
Board seatFrancesco De Rubertis· per SEC Form D
Co-investorsLongitude CapitalRA Capital
Zephyr AI is a healthcare technology company.
AI & Machine LearningBiotechDigital HealthDallas, US
Grant Verstandig(Director)Yisroel Brumer(Director)Jeff Sherman(Executive Officer)David Morgan(Executive Officer)Ken Samet(Director)Sol Barer(Director)
Board seatMoncef Slaoui· per SEC Form D · $120.7M raise · filed Mar 2024
Co-investorsRevolution
Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersClaret Capital PartnersSamsara BioCapitalSofinnova PartnersTruffle Capital
Co-investorsAdvent Life SciencesForesite CapitalScion Life Sciences
CookieYes is a cookie consent management platform that helps businesses comply with global data privacy regulations including GDPR, CPRA, and LGPD.
AdTechEnterprise SoftwareSaaSUnited Kingdom, India
Anvar T K(Founder)in
Co-investorsAdvantage Capital PartnersBrighteye VenturesCapitânia InvestimentosChemistryE4E AfricaEight Roads Ventures+20 more
Curevo Vaccine is a clinical-stage biotech company developing non-mRNA vaccines, with a lead adjuvanted subunit vaccine candidate (amezosvatein/CRV-101) for shingles and chickenpox.
BiotechHealthtech
Co-investorsAdjuvant CapitalOrbiMedRA CapitalSanofi VenturesHBM Healthcare InvestmentsJanus Henderson Investors
BiotechHealthtechCleveland, US
Robert Geho(Executive Officer, Director)W. Blair Geho(Executive Officer, Director)Helga Kautsky(Executive Officer)
BoardMichele Ollier(Director)Guiseppe Zocco(Director)Richard Caruso(Director)
Co-investorsJDRF T1D Fund
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsLG Technology VenturesNovartis Venture FundOrbiMedPontifax Venture CapitalWindham Capital PartnersSymBiosis
Imhotex is a virtual biopharmaceutical company developing a drug candidate to treat Crohn's Disease, a form of inflammatory bowel disease.
BiotechHealthtechCambridge, GB
A therapeutics company developing checkpoint agonist antibodies for autoimmune disease treatment based on Oxford University research (exited August 2022).
Co-investorsAdvent Life SciencesMonograph Capital PartnersOxford Science EnterprisesSamsara BioCapital
Co-investorsForesite Capital
Vaderis is a biotech company developing therapies for people with hereditary hemorrhagic telangiectasia (HHT) and other rare vascular diseases.
BiotechHealthtech
Co-investorsDroia Ventures
AI & Machine LearningBiotechHealthtech
PartnerGiovanni Mariggi· led
Co-investorsAvoro Capital AdvisorsTCG CrossoverUniQuest Extension Fund (UEF)venBio Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.